Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (28 items missing)
No data available for the selected time periods
in million USD FY '07FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Product sales
2,170
2,754
2,694
3,128
3,845
4,253
4,758
5,830
6,100
Royalties
247
246
293
328
284
242
154
161
301
Other revenues
19
23
22
15
30
33
23
31
16
Total revenues
2,436
3,022
3,008
3,471
4,158
4,527
4,934
6,022
6,417
Cost of product sales
320
408
388
463
552
586
671
979
969
Research and development
545
494
640
662
765
953
933
1,068
1,564
Selling, general and administrative
1,211
1,455
1,343
1,526
1,676
1,948
1,651
2,026
2,341
Goodwill impairment charge
0
0
0
0
0
0
199
0
0
Gain on sale of product rights
-128
-21
-6
-17
6
-18
-16
-55
-15
In-process R&D ("IPR&D") charge
1,866
263
0
0
0
0
0
0
0
Reorganization costs
0
0
13
34
24
0
88
181
98
Integration and acquisition costs
1
10
11
8
0
14
-134
159
40
Total operating expenses
3,815
2,610
2,388
2,677
3,022
3,482
3,201
4,324
4,997
Operating income from continuing operations
-1,379
412
620
794
1,136
1,045
1,734
1,698
1,420
Interest income
51
26
2
2
2
3
2
25
4
Interest expense
-71
-139
-40
-35
-39
-38
-38
-31
-42
Other income/(expense), net
1
-33
61
8
19
-2
-4
9
4
Total other expense, net
-19
-146
23
-25
-19
0
0
0
0
Receipt of break fee
0
0
0
0
0
0
0
1,635
0
Income from continuing operations before income taxes and equity in (losses)/earnings of equity method investees
-1,398
266
643
769
1,117
1,008
1,694
3,336
1,386
Income taxes
-56
-98
-139
-183
-237
-203
-278
-56
-46
Equity in (losses)/earnings of equity method investees, net of taxes
2
2
-1
1
3
1
4
3
-2
Income from continuing operations, net of taxes
-1,452
170
504
0
883
806
1,420
3,283
1,338
(Loss)/gain from discontinued operations, net of taxes (in USD)
0
-18
-12
0
-18
-60
-755
123
-34
Net income
-1,452
152
491
0
0
0
0
0
0
Add: Net loss attributable to the noncontrolling interest in subsidiaries
0
4
0
0
0
0
0
0
0
Net income attributable to Shire plc
-1,452
156
492
588
865
745
665
3,406
1,303
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 23, 2012 n/a
calculated values,
restated on Feb 25, 2013 n/a
calculated values,
restated on Feb 24, 2014 n/a
calculated values,
restated on Feb 24, 2015 n/a
calculated values,
restated on Feb 23, 2016 n/a
calculated values,
restated on Feb 23, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (36 items missing)
No data available for the selected time periods
in million USD FY '07FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
218
499
551
620
1,482
2,239
2,982
136
Restricted cash
n/a
29
33
27
21
17
22
55
86
Accounts receivable, net
n/a
395
598
693
845
824
961
1,035
1,201
Inventories
n/a
155
190
260
340
437
455
545
635
Assets held for sale
n/a
17
0
0
0
0
32
0
0
Deferred tax asset
n/a
90
136
182
208
230
316
345
0
Prepaid expenses and other current assets
n/a
141
115
168
175
222
263
222
197
Total current assets
n/a
1,044
1,570
1,880
2,208
3,212
4,288
5,183
2,256
Investments
n/a
43
106
102
30
39
32
44
51
Property, plant and equipment, net
n/a
534
677
853
932
956
892
838
828
Goodwill
n/a
351
385
403
593
645
625
2,475
4,148
Other intangible assets, net
n/a
1,825
1,791
1,979
2,493
2,388
2,313
4,934
9,173
Deferred tax asset
n/a
118
79
110
51
47
141
112
121
Other non-current assets
n/a
18
10
61
74
32
33
46
33
Total assets
n/a
3,934
4,618
5,388
6,380
7,317
8,323
13,632
16,610
Liabilities and owners' equity
Accounts payable and accrued expenses
n/a
709 708600000
929 929100000
1,239 1239300000
1,371 1370500000
1,502 1501500000
1,688 1688400000
1,909 1909400000
2,051 2050600000
Convertible bonds
n/a
0 0
0 0
0 0
1,100 1100000000
0 0
0 0
0 0
0 0
Deferred tax liability
n/a
11 10900000
3 2900000
4 4400000
0 0
0 0
0 0
0 0
0 0
Short-term borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
850 850000000
1,512 1511500000
Other current liabilities
n/a
104 104300000
88 88000000
50 49600000
64 63800000
144 144100000
120 119500000
263 262500000
144 144000000
Total current liabilities
n/a
824 823800000
1,020 1020000000
1,293 1293300000
2,534 2534300000
1,646 1645600000
1,808 1807900000
3,022 3021900000
3,706 3706100000
Convertible bonds
n/a
1,100 1100000000
1,100 1100000000
1,100 1100000000
0 0
1,100 1100000000
0 0
0 0
0 0
Long-term borrowings
n/a
43 43100000
44 43600000
0 0
0 0
0 0
0 0
0 0
70 69900000
Deferred tax liability
n/a
348 348000000
294 294300000
352 352100000
517 516600000
521 520800000
561 560600000
1,211 1210600000
2,206 2205900000
Other non-current liabilities
n/a
291 291300000
247 247100000
191 190800000
144 144300000
242 241600000
589 588500000
737 736700000
799 798800000
Total liabilities
n/a
2,606 2606200000
2,705 2705000000
2,936 2936200000
3,195 3195200000
3,508 3508000000
2,957 2957000000
4,969 4969200000
6,781 6780700000
Commitments and contingencies
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Common stock
n/a
56 55500000
56 55600000
56 55700000
56 55700000
56 55700000
59 58600000
59 58700000
59 58900000
Additional paid-in capital
n/a
2,595 2594600000
2,678 2677600000
2,746 2746400000
2,853 2853300000
2,982 2981500000
4,186 4186300000
4,338 4338000000
4,486 4486300000
Treasury stock
n/a
-397 -397200000
-347 -347400000
-276 -276100000
-287 -287200000
-310 -310400000
-451 -450600000
-346 -345900000
-321 -320600000
Accumulated other comprehensive loss
n/a
97 97000000
149 149100000
86 85700000
60 60300000
87 86900000
110 110200000
-32 -31500000
-184 -183800000
Retained earnings
n/a
-1,023 -1022700000
-622 -622400000
-160 -160300000
503 502900000
996 995500000
1,462 1461500000
4,644 4643600000
5,788 5788300000
Total equity
n/a
1,327 1327200000
0 0
0 0
3,185 3185000000
3,809 3809200000
5,366 5366000000
8,663 8662900000
9,829 9829100000
Noncontrolling interest in subsidiaries'
n/a
0 300000
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
n/a
1,328 1327500000
1,913 1912500000
2,451 2451400000
0 0
0 0
0 0
0 0
0 0
Total liabilities and equity
n/a
3,934 3933700000
4,618 4617500000
5,388 5387600000
6,380 6380200000
7,317 7317200000
8,323 8323000000
13,632 13632100000
16,610 16609800000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Feb 23, 2011 n/a restated on Feb 23, 2012 n/a restated on Feb 25, 2013 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (71 items missing)
No data available for the selected time periods
in million USD FY '07FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net income
-1,452
152
491
588
865
745
665
3,406
1,303
Loss from discontinued operations
0
18
12
0
0
0
0
0
0
Depreciation and amortization
158
203
250
256
295
309
324
407
637
Share-based compensation
75
65
66
62
76
87
77
97
100
IPR&D charge
1,866
128
0
0
0
0
0
0
0
Change in fair value of contingent consideration
0
0
0
0
0
9
-159
15
-150
Impairment of intangible assets
0
97
0
43
16
198
20
190
644
Goodwill impairment charge
0
0
0
0
0
0
199
0
0
Impairment of assets held for sale
3
58
0
0
0
0
637
0
0
Write down of assets
0
0
0
0
0
1
58
0
0
Gain on sale of non-current investments
0
-10
-55
-11
-24
0
0
0
0
Gain on sale of product rights
-128
-21
-6
-17
6
-18
-16
-55
-15
Unwind of inventory fair value step-ups
0
0
0
0
0
0
0
92
31
Other, net
14
11
15
9
16
7
11
29
13
Movement in deferred taxes
-25
74
-99
-15
-15
-58
-350
-14
-198
Equity in losses/(earnings) of equity method investees
-2
-2
1
-1
-3
-1
-4
-3
2
Increase in accounts receivable
-121
9
-212
-114
-134
22
-148
-66
-211
Iincrease in sales deduction accruals
24
84
135
223
81
43
178
108
98
Increase in inventory
-46
36
-39
-58
-64
-88
-37
-25
-63
Decrease/(increase) in prepayments and other assets
-10
-10
31
-40
-37
-15
-61
42
37
(Increase)/decrease in other assets
1
4
0
0
0
0
0
0
0
Increase in accounts and notes payable and other liabilities
109
-99
39
26
-10
137
68
5
109
Returns on investment from joint venture
7
7
5
6
5
5
0
0
0
Cash flows used in discontinued operations
0
-5
-6
0
0
0
0
0
0
Net cash provided by operating activities
475
800
627
955
1,074
1,383
1,463
4,228
2,337
Movements in short-term investments
56
0
0
0
0
0
0
0
0
Movements in restricted cash
-10
10
-4
6
6
4
-5
-33
-32
Purchases of subsidiary undertakings and businesses, net of cash acquired
-2,520
-499
-83
-450
-725
-97
-228
-4,104
-5,553
Payment on settlement of Transkaryotic Therapies, Inc. ("TKT") appraisal right litigation
0
-420
0
0
0
0
0
0
0
Payments on foreign exchange contracts related to Movetis NV ("Movetis") acquisition
0
0
0
-33
0
0
0
0
0
Purchases of non-current investments
-63
-2
-1
-3
-11
-18
-11
-23
-10
Purchases of PP&E
-110
-236
-254
-327
-194
-150
-157
-77
-115
Purchases of intangible assets
-59
-25
-7
-3
-5
-44
0
0
0
Proceeds from disposal of property, plant and equipment
1
0
0
0
0
0
0
0
0
Proceeds from short-term investments
0
0
0
0
0
0
0
58
67
Proceeds received on sale of product rights
234
5
0
2
12
18
19
127
18
Proceeds from disposal of subsidiary undertakings
0
0
7
0
0
0
0
0
0
Return on investments
2
1
0
7
0
0
0
0
0
Proceeds from disposal of non-current investments
1
12
20
2
106
7
12
22
19
Proceeds from capital expenditure grants
0
0
0
0
0
0
0
0
0
Other, net
0
0
0
0
2
9
9
0
-14
Net cash used in investing activities
-2,468
-1,155
-322
-797
-809
-271
-361
-4,031
-5,620
Proceeds from revolving line of credit, long-term and short-term borrowings
1,300
190
0
0
30
0
0
2,311
3,761
Repayment of revolving line of credit, long term and short term borrowings
0
-190
0
0
-30
0
0
-1,462
-3,111
Proceeds from issue of Shire plc 2.75% convertible bonds due 2014
1,100
0
0
0
0
0
0
0
0
Redemption of New River 3.5% convertible note due 2013
-279
0
0
0
0
0
0
0
0
Proceeds from exercise of New River purchased call option
142
0
0
0
0
0
0
0
0
Payment of debt arrangement and issue costs
-33
0
0
0
0
0
0
0
0
Payment under building finance obligation
0
-2
-5
0
0
0
0
0
0
Repayment of debt acquired through business combinations
-1,300
0
0
0
-13
0
0
-552
0
Extinguishment of building finance obligation
0
11
0
-43
0
0
0
0
0
Proceeds from ViroPharma call options
0
0
0
0
0
0
0
347
0
Payment of dividend
-41
-47
-54
-62
-74
-86
-96
-121
-134
Payments to acquire shares (in USD)
-186
-147
-1
-2
-152
-206
-244
0
0
Excess tax benefit associated with exercise of stock options
0
0
17
7
31
41
13
40
32
Costs associated with issue of common stock, net
0
-6
0
0
0
0
0
0
0
Proceeds from exercise of options
30
11
15
11
13
16
17
17
17
Proceeds from exercise of warrants
13
0
0
0
0
0
0
0
0
Proceeds from issuance of common stock
877
0
0
0
0
0
0
0
0
Facility arrangement fee
0
0
0
-8
0
0
-14
-10
-24
Contingent consideration payments
0
0
0
0
0
-6
-14
-15
-101
Other, net
0
0
0
-2
-2
-3
-7
0
0
Net cash provided by/(used in) financing activities
1,623
-178
-29
-100
-195
-244
-345
555
439
Effect of foreign exchange rate changes on cash and cash equivalents
6
-12
5
-6
0
-5
0
-9
-3
Net (decrease)/increase in cash and cash equivalents
-364
-544
281
52
69
862
757
743
-2,847
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 23, 2012 n/a
calculated values,
restated on Feb 25, 2013 n/a
calculated values,
restated on Feb 24, 2014 n/a
calculated values,
restated on Feb 24, 2015 n/a
calculated values,
restated on Feb 23, 2016 n/a
calculated values,
restated on Feb 23, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Sumo